JP2015061536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015061536A5 JP2015061536A5 JP2014255610A JP2014255610A JP2015061536A5 JP 2015061536 A5 JP2015061536 A5 JP 2015061536A5 JP 2014255610 A JP2014255610 A JP 2014255610A JP 2014255610 A JP2014255610 A JP 2014255610A JP 2015061536 A5 JP2015061536 A5 JP 2015061536A5
- Authority
- JP
- Japan
- Prior art keywords
- ephb4
- ephrin
- cellular material
- cell
- epc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000463 material Substances 0.000 claims 9
- 102000006396 Ephrin-B2 Human genes 0.000 claims 8
- 108010044090 Ephrin-B2 Proteins 0.000 claims 8
- 230000001413 cellular effect Effects 0.000 claims 8
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims 6
- 230000002491 angiogenic effect Effects 0.000 claims 6
- 239000003446 ligand Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000002771 cell marker Substances 0.000 claims 5
- 210000005087 mononuclear cell Anatomy 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 4
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 4
- 210000004700 fetal blood Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 210000005259 peripheral blood Anatomy 0.000 claims 4
- 239000011886 peripheral blood Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 108010033276 Peptide Fragments Proteins 0.000 claims 3
- 102000007079 Peptide Fragments Human genes 0.000 claims 3
- 206010054880 Vascular insufficiency Diseases 0.000 claims 3
- 102000023732 binding proteins Human genes 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 210000004204 blood vessel Anatomy 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 208000023577 vascular insufficiency disease Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical class 0.000 claims 1
- 206010003230 arteritis Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0508029 | 2005-07-27 | ||
| FR0508029A FR2889200B1 (fr) | 2005-07-27 | 2005-07-27 | Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008523415A Division JP5755829B2 (ja) | 2005-07-27 | 2006-07-27 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016050940A Division JP6235639B2 (ja) | 2005-07-27 | 2016-03-15 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015061536A JP2015061536A (ja) | 2015-04-02 |
| JP2015061536A5 true JP2015061536A5 (enExample) | 2015-07-09 |
| JP5981525B2 JP5981525B2 (ja) | 2016-08-31 |
Family
ID=36353668
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008523415A Expired - Fee Related JP5755829B2 (ja) | 2005-07-27 | 2006-07-27 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
| JP2014255610A Expired - Fee Related JP5981525B2 (ja) | 2005-07-27 | 2014-12-17 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
| JP2016050940A Expired - Fee Related JP6235639B2 (ja) | 2005-07-27 | 2016-03-15 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
| JP2017121385A Pending JP2017169590A (ja) | 2005-07-27 | 2017-06-21 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008523415A Expired - Fee Related JP5755829B2 (ja) | 2005-07-27 | 2006-07-27 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016050940A Expired - Fee Related JP6235639B2 (ja) | 2005-07-27 | 2016-03-15 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
| JP2017121385A Pending JP2017169590A (ja) | 2005-07-27 | 2017-06-21 | Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8338169B2 (enExample) |
| EP (1) | EP1913130B1 (enExample) |
| JP (4) | JP5755829B2 (enExample) |
| CN (1) | CN101273123B (enExample) |
| AU (1) | AU2006273928B2 (enExample) |
| CA (1) | CA2616712C (enExample) |
| DK (1) | DK1913130T3 (enExample) |
| ES (1) | ES2565675T3 (enExample) |
| FR (1) | FR2889200B1 (enExample) |
| IL (1) | IL188938A (enExample) |
| WO (1) | WO2007012764A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2909559B1 (fr) * | 2006-12-06 | 2012-09-07 | Inst Vaisseaux Et Du Sang | Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation |
| AU2008223817A1 (en) | 2007-03-02 | 2008-09-12 | National University Of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
| FR2957799B1 (fr) * | 2010-03-26 | 2012-08-17 | Inst Des Vaisseaux Et Du Sang | Compositions proangiogeniques, leur procede de preparation et leurs utilisations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4240635C2 (de) * | 1992-12-03 | 1997-07-10 | Lothar Prof Dr Kanz | Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren |
| US5980887A (en) * | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| WO2000031124A2 (en) | 1998-11-20 | 2000-06-02 | Mount Sinai Hospital | Peptides that modulate the interaction of b class ephrins and pdz domains |
| US6610534B2 (en) | 2000-10-05 | 2003-08-26 | Novartis Ag | Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases |
| AU2002243623A1 (en) | 2001-01-26 | 2002-08-06 | Regeneron Pharmaceuticals, Inc. | Methods of imaging and targeting vasculature |
| AU2002311792A1 (en) | 2001-03-30 | 2002-10-15 | President And Fellows Of Harvard College | B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use |
| US20050049194A1 (en) | 2001-11-09 | 2005-03-03 | Jonas Frisen | Use of ephrins and related molecules to regulate cellular proliferation |
| AU2003232457A1 (en) | 2002-05-29 | 2003-12-19 | Curagen Corporation | Compositions and methods of use for an ephrin rreceptor |
| US20040110150A1 (en) | 2002-12-10 | 2004-06-10 | Isis Pharmaceuticals Inc. | Modulation of Ephrin-B2 expression |
| US7576074B2 (en) | 2002-07-15 | 2009-08-18 | Rice Kenneth D | Receptor-type kinase modulators and methods of use |
| AU2003900541A0 (en) | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
| AU2004220459B2 (en) | 2003-03-12 | 2010-08-05 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
-
2005
- 2005-07-27 FR FR0508029A patent/FR2889200B1/fr not_active Expired - Lifetime
-
2006
- 2006-07-27 US US11/996,862 patent/US8338169B2/en not_active Expired - Fee Related
- 2006-07-27 EP EP06794234.2A patent/EP1913130B1/fr active Active
- 2006-07-27 CA CA2616712A patent/CA2616712C/fr not_active Expired - Fee Related
- 2006-07-27 AU AU2006273928A patent/AU2006273928B2/en not_active Ceased
- 2006-07-27 CN CN2006800358867A patent/CN101273123B/zh not_active Expired - Fee Related
- 2006-07-27 JP JP2008523415A patent/JP5755829B2/ja not_active Expired - Fee Related
- 2006-07-27 DK DK06794234.2T patent/DK1913130T3/en active
- 2006-07-27 ES ES06794234.2T patent/ES2565675T3/es active Active
- 2006-07-27 WO PCT/FR2006/001837 patent/WO2007012764A2/fr not_active Ceased
-
2008
- 2008-01-22 IL IL188938A patent/IL188938A/en active IP Right Grant
-
2014
- 2014-12-17 JP JP2014255610A patent/JP5981525B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-15 JP JP2016050940A patent/JP6235639B2/ja not_active Expired - Fee Related
-
2017
- 2017-06-21 JP JP2017121385A patent/JP2017169590A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Stem cell recruitment and angiogenesis of neuropeptide substance P coupled with self-assembling peptide nanofiber in a mouse hind limb ischemia model | |
| Liao et al. | Endothelial progenitor cells for ischemic stroke: update on basic research and application | |
| UA130113C2 (uk) | Мутеїн інтерлейкіну-21 | |
| JP2019520365A5 (enExample) | ||
| Heyboer III et al. | CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen—changes with oxygen dosage | |
| Hou et al. | Cardiac stem cells and their roles in myocardial infarction | |
| Li et al. | Enhanced migration of bone marrow-derived mesenchymal stem cells with tetramethylpyrazine and its synergistic effect on angiogenesis and neurogenesis after cerebral ischemia in rats | |
| HRP20211715T1 (hr) | Trans-replicirajuća rnk | |
| JP2016519933A5 (enExample) | ||
| JP2019519528A5 (enExample) | ||
| EP4349854A3 (en) | Pd1-cd28 fusion proteins and their use in medicine | |
| JP2019521976A5 (enExample) | ||
| SV2016005145A (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca | |
| Hassanshahi et al. | Critical limb ischemia: Current and novel therapeutic strategies | |
| Hayon et al. | The role of platelets and their microparticles in rehabilitation of ischemic brain tissue | |
| WO2018069408A4 (en) | A COMPOSITION OF EXTRACELLULAR VESICLES (EVs) AND MEDICAL USES THEREOF | |
| JP2015061536A5 (enExample) | ||
| CN114938630A (zh) | 用于心脏修复的永生化心脏干细胞 | |
| JP2023105066A (ja) | 組織治癒剤 | |
| US12421491B2 (en) | Composition for increasing biological activity of stem cells using mixture 4F | |
| EA202092396A1 (ru) | Новые способы лечения интерстициальных заболеваний легких | |
| Poglajen et al. | Stem cell therapy for chronic and advanced heart failure | |
| Kotenko et al. | Cell technologies in the treatment of radiation burns: experience Burnasyan Federal Medical Biophysical Centre | |
| Turksen | Adult stem cells and cardiac regeneration | |
| Hiesinger et al. | Re-Engineered Stromal Cell–Derived Factor-1α and the Future of Translatable Angiogenic Polypeptide Design |